SGLT-2 Inhibitors and GLP-1 Receptor Agonists Redefine Cardiovascular Prevention in Cardiometabolic Disease

Cardiometabolic disease (CMD), driven by the rising prevalence of obesity, type 2 diabetes (T2D), and cardiovascular disease (CVD), represents a major 21st-century health challenge. Despite the established link between hyperglycemia and diabetic complications, a glucose-centered approach to T2D management has shown limited impact on major cardiovascular outcomes, often with safety concerns narrowing overall clinical benefit. This gap highlights the urgent need for therapies that address the broader burden of cardiovascular and renal disease more effectively, moving beyond mere glycemic control.

This comprehensive review synthesizes the evolving understanding of sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists). It examines how these drug classes, initially developed for type 2 diabetes, have fundamentally altered the treatment landscape by demonstrating significant protective effects on major adverse cardiovascular events (MACE) and kidney outcomes. The authors discuss their mechanisms of action and implications for redefining cardiometabolic disease prevention strategies, moving beyond a glucose-centric paradigm.

This review highlights that SGLT-2 inhibitors and GLP-1 receptor agonists offer substantial cardiovascular and renal protection that extends significantly beyond their primary glucose-lowering effects. These agents have consistently demonstrated a reduction in the risk of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death, as well as providing significant benefits in heart failure and chronic kidney disease outcomes. The authors emphasize that these broad protective effects are observed across a spectrum of cardiometabolic conditions, not exclusively in patients with type 2 diabetes. This collective evidence suggests a paradigm shift in therapeutic strategy.

"These therapies represent a paradigm shift, moving beyond a glucose-centric approach to T2D management towards comprehensive cardiometabolic risk reduction and prevention." The review underscores that the benefits of these drug classes are now recognized as crucial for improving long-term prognosis in individuals at high cardiometabolic risk, irrespective of their glycemic status.